Milestones

1. Fluvastatin, a cholesterol biosynthesis inhibitor, stimulates macrophage inflammatory response to Mycobacterium tuberculosis H37Ra (Montero MT, Matilla J, Bazán E, Reimers D, De Andrés A, Gonzalo R, Correa C, Urbano F, Gómez D. Fluvastatin Converts Human Macrophages into Foam Cells with Increased Infl ammatory Response to Inactivated Mycobacterium tuberculosis H37Ra. Cells. 2024;13(6): 536. DOI:10.3390/cells13060536).
2. The TRPML1 agonist, ML-SA1, mitigates antipsychotic-induced intracellular lipid accumulation in vitro by stimulating the release of extracellular microvesicles (Chavarría-Cubel et al. In review in Biochim Biophys Acta, BBALIP-24-304).
3. Characterization of a vitamin E-derived compound that delays the progression of metabolic hepatic steatosis in an animal model (PI21/01173, ISCIII).
4. Designation as organizer (O.P.R.) and next venue of the 4th International Lipidomics Society (ILS) Conference, Madrid 2025 (https://lipidomicssociety.org/events/ils-2025/).
5. Specific IgE determination and basophil activation test by microarray are promising tools for the diagnosis of hypersensitivity reactions to platinum compounds (Fernández C, Rita CG, Barra A, De La Hoz B, Roldán E, Pueyo C, Martínez J, Berges MP. Specific IgE and Basophil Activation Test by Microarray: A Promising Tool for Diagnosis of Platinum Compound Hypersensitivity Reactions. Int J Mol Sci. 2024;25(7): 3890. DOI:10.3390/ijms25073890).